A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease

NCT03765762 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Alzheimer Disease

Interventions

DRUG: GRF6019
OTHER: Placebo

Sponsor

Alkahest, Inc.